Tags

Type your tag names separated by a space and hit enter

Specific K39 antibody response and its persistence after treatment in patients with imported leishmaniasis.
Parasitol Res. 2016 Feb; 115(2):761-9.PR

Abstract

The sensitivity of a K39 ELISA (Leishmania IgG, Virion/Serion) for the detection of antibodies in patients with imported leishmaniasis was compared with an immunofluorescence assay (IFA), which was applied as "golden standard". The retrospective study comprised 93 IFA-positive or borderline sera from 42 patients with visceral (n = 16) or cutaneous (n = 26) leishmaniasis. Patients had acquired infection predominately in the Mediterranean area or the Middle East. The Leishmania species (Leishmania donovani/infantum, Leishmania tropica, Leishmania major) were identified by real-time PCR. The majority (94%) of first samples from patients with visceral leishmaniasis (VL) tested positive by K39 ELISA. Antibody levels ranged from low to very high (33.19-1990.00 U/ml; median 596.66 U/ml) but did not correlate with the respective IFA titers. High K39 ELISA values correlated with acute infection in immunocompetent individuals. K39 antibodies declined in all individuals after clinically successful therapy, but time to seronegativity varied considerably (51 weeks to >6 years). In patients with cutaneous leishmaniasis (CL), the sensitivity of the K39 ELISA was low (23%) compared to IFA (92% positive). Antibody levels ranged from low to medium (10.85-524.77 U/ml; median 19.77 U/ml). The highest antibody concentrations were seen in L. infantum-infected individuals. Summarizing, a high K39 ELISA value indicates active VL. The assay is, like IFA, not a measure for effective therapy but may support post-treatment monitoring. Low level positivity can indicate subclinical, previous or clinically cured VL or even CL. The K39 ELISA can supplement highly sensitive screening tests in the diagnosis and follow-up of imported leishmaniasis.

Authors+Show Affiliations

Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie, Universitätsklinikum, Bonn, Germany. reiter-owona@microbiology-bonn.de.Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Bonn, Sigmund-Freud Str.25, 53105, Bonn, Germany.Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie, Universitätsklinikum, Bonn, Germany.Institut Virion/Serion GmbH, 97076, Würzburg, Germany.Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie, Universitätsklinikum, Bonn, Germany.Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie, Universitätsklinikum, Bonn, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26508007

Citation

Reiter-Owona, Ingrid, et al. "Specific K39 Antibody Response and Its Persistence After Treatment in Patients With Imported Leishmaniasis." Parasitology Research, vol. 115, no. 2, 2016, pp. 761-9.
Reiter-Owona I, Rehkaemper-Schaefer C, Arriens S, et al. Specific K39 antibody response and its persistence after treatment in patients with imported leishmaniasis. Parasitol Res. 2016;115(2):761-9.
Reiter-Owona, I., Rehkaemper-Schaefer, C., Arriens, S., Rosenstock, P., Pfarr, K., & Hoerauf, A. (2016). Specific K39 antibody response and its persistence after treatment in patients with imported leishmaniasis. Parasitology Research, 115(2), 761-9. https://doi.org/10.1007/s00436-015-4801-8
Reiter-Owona I, et al. Specific K39 Antibody Response and Its Persistence After Treatment in Patients With Imported Leishmaniasis. Parasitol Res. 2016;115(2):761-9. PubMed PMID: 26508007.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Specific K39 antibody response and its persistence after treatment in patients with imported leishmaniasis. AU - Reiter-Owona,Ingrid, AU - Rehkaemper-Schaefer,Claudia, AU - Arriens,Sandra, AU - Rosenstock,Philip, AU - Pfarr,Kenneth, AU - Hoerauf,Achim, Y1 - 2015/10/28/ PY - 2015/08/18/received PY - 2015/10/19/accepted PY - 2015/10/29/entrez PY - 2015/10/29/pubmed PY - 2016/9/17/medline KW - Diagnosis KW - IFA KW - Imported leishmaniasis KW - K39 ELISA KW - Leishmaniasis KW - Treatment SP - 761 EP - 9 JF - Parasitology research JO - Parasitol Res VL - 115 IS - 2 N2 - The sensitivity of a K39 ELISA (Leishmania IgG, Virion/Serion) for the detection of antibodies in patients with imported leishmaniasis was compared with an immunofluorescence assay (IFA), which was applied as "golden standard". The retrospective study comprised 93 IFA-positive or borderline sera from 42 patients with visceral (n = 16) or cutaneous (n = 26) leishmaniasis. Patients had acquired infection predominately in the Mediterranean area or the Middle East. The Leishmania species (Leishmania donovani/infantum, Leishmania tropica, Leishmania major) were identified by real-time PCR. The majority (94%) of first samples from patients with visceral leishmaniasis (VL) tested positive by K39 ELISA. Antibody levels ranged from low to very high (33.19-1990.00 U/ml; median 596.66 U/ml) but did not correlate with the respective IFA titers. High K39 ELISA values correlated with acute infection in immunocompetent individuals. K39 antibodies declined in all individuals after clinically successful therapy, but time to seronegativity varied considerably (51 weeks to >6 years). In patients with cutaneous leishmaniasis (CL), the sensitivity of the K39 ELISA was low (23%) compared to IFA (92% positive). Antibody levels ranged from low to medium (10.85-524.77 U/ml; median 19.77 U/ml). The highest antibody concentrations were seen in L. infantum-infected individuals. Summarizing, a high K39 ELISA value indicates active VL. The assay is, like IFA, not a measure for effective therapy but may support post-treatment monitoring. Low level positivity can indicate subclinical, previous or clinically cured VL or even CL. The K39 ELISA can supplement highly sensitive screening tests in the diagnosis and follow-up of imported leishmaniasis. SN - 1432-1955 UR - https://www.unboundmedicine.com/medline/citation/26508007/Specific_K39_antibody_response_and_its_persistence_after_treatment_in_patients_with_imported_leishmaniasis_ L2 - https://dx.doi.org/10.1007/s00436-015-4801-8 DB - PRIME DP - Unbound Medicine ER -